Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. [electronic resource]
Producer: 20061026Description: 756-62 p. digitalISSN:- 1464-4096
- Adult
- Aged
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Axitinib
- Bevacizumab
- Carcinoma, Renal Cell -- complications
- Female
- Humans
- Imidazoles -- administration & dosage
- Indazoles -- administration & dosage
- Indoles -- administration & dosage
- Kidney Neoplasms -- complications
- Male
- Middle Aged
- Mutation -- genetics
- Pyrroles -- administration & dosage
- Sunitinib
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- drug effects
- von Hippel-Lindau Disease -- complications
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.